- COMMENT
INCATE: a partnership to boost the antibiotic pipeline
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 21, 621-622 (2022)
doi: https://doi.org/10.1038/d41573-022-00138-7
Acknowledgements
The authors thank all colleagues and partners involved in INCATE (Supplementary Table 1). This work was supported by the National Center of Competence in Research AntiResist funded by the Swiss National Science Foundation (grant number 180541).
References
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).
Plackett, B. Why big pharma has abandoned antibiotics. Nature 586, S50–S52 (2020).
Cookson, C. UK launches world-first “subscription” model for antibiotic supply. Financial Times https://www.ft.com/content/c7cbebe4-8597-4340-8c55-56c4b423c1d1 (2022).
World Bank Group: Drug-resistant infections: a threat to our economic future. https://documents.worldbank.org/en/publication/documents-reports/documentdetail/323311493396993758/final-report (2017).
Cueni, T. B. Four priority actions to slow the silent pandemic of antimicrobial resistance. Health Policy Watch https://healthpolicy-watch.news/slow-the-silent-pandemic-of-antimicrobial-resistance/ (2022).
Supplementary Information
Competing Interests
The authors declare no competing interests.